Physician profile
Samarth Virmani
NPI 1093274276
$805.76
in general payments reported to CMS, 2019-2025
11 companies · $477 in 2025
The $477 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $118 · 2024: $211 · 2025: $477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $237.96 | 2024-2025 | Korlym |
| Kyowa Kirin, INC. | $135.13 | 2023-2024 | Crysvita |
| Xeris Pharmaceuticals, INC. | $85.45 | 2025 | Recorlev |
| Alexion Pharmaceuticals, INC. | $81.97 | 2025 | Strensiq |
| Radius Health, INC. | $49.54 | 2024 | Tymlos |
| Amgen INC. | $47.30 | 2025 | Evenity |
| Lilly USA, LLC | $44.98 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $44.84 | 2025 | Wegovy |
| Chiesi USA, INC. | $36.77 | 2025 | Juxtapid |
| Recordati_rare_diseases_inc. | $23.07 | 2025 | Isturisa |
| Madrigal Pharmaceuticals | $18.75 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samarth Virmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.